July 22, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing new adverse reaction risks for a batch of medicines including Pfizer’s Xeljanz (tofacitinib) - a move likely to trigger a label change in the near future - according to the agency’s...read more